Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

Roche's Perjeta pertuzumab

European approval for Roche’s next-gen breast cancer drug

Perjeta now available in EU for use before surgery in early stage aggressive breast cancer

- PMLiVE

Roche pharma sales strong for first half of 2015

New and old cancer drugs boost revenue for the Swiss pharma firm

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

Novartis building

US ruling clears Novartis’ Zarxio but could delay other biosimilars

Federalcourt's complex ruling could have a wide-ranging impact

- PMLiVE

The evolving biosimilars market

Safety and efficacy doubts remain a challenge

Bristol-Myers Squibb (BMS) building

BMS’ HIV combination Evotaz cleared in Europe

Comes after the firm recently announced it would shelve much of its virology unit

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

Roche Basel Switzerland

Roche’s breakthrough PD-L1 drug slows cancer growth

Latest positive trial for the firm’s next-gen oncology product atezolizumab

EU flag

Greek ‘no’ vote puts pharma in tricky position

Pharma claims there is no need for concern regarding medicine supply

- PMLiVE

Roche and Evotec’s Alzheimer’s drug ineffective

Sembragiline failed to show cognitive and memory benefits

Roche Basel Switzerland

Roche planning ocrelizumab filings in early 2016

Firm claims MS candidate outperformed Merck Serono’s Rebif in two phase III trials

- PMLiVE

NHS sponsors charity on metastatic breast cancer study

Breast Cancer Now to study tissue shortly after death

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links